Structures by: Henry R. F.
Total: 66
C27H28ClN2O5
C27H28ClN2O5
Organic letters (2007) 9, 7 1299-1302
a=12.239(7)Å b=22.483(12)Å c=9.188(5)Å
α=90.00° β=103.324(12)° γ=90.00°
Caffeine 3-hydroxy-2-naphthoic acid
C8H10N4O2,C11H8O3
Molecular Pharmaceutics (2007) 4, 3 339
a=9.040(9)Å b=24.42(2)Å c=8.654(8)Å
α=90.00° β=117.015(14)° γ=90.00°
Caffeine 1-hydroxy-2-naphthoic acid
C8H10N4O2,C11H8O3
Molecular Pharmaceutics (2007) 4, 3 339
a=7.6063(17)Å b=14.042(3)Å c=16.327(4)Å
α=90.00° β=94.030(4)° γ=90.00°
C8H10N4O2,C11H8O3
C8H10N4O2,C11H8O3
Molecular Pharmaceutics (2007) 4, 3 339
a=8.029(3)Å b=8.592(3)Å c=13.996(5)Å
α=106.475(5)° β=98.162(5)° γ=104.904(6)°
C18H19N3O2
C18H19N3O2
Organic letters (2007) 9, 24 5119-5122
a=14.023(3)Å b=13.658(3)Å c=17.593(5)Å
α=90.00° β=113.469(3)° γ=90.00°
C17H20N2O2
C17H20N2O2
Organic letters (2007) 9, 24 5119-5122
a=24.724(4)Å b=9.0148(14)Å c=17.464(3)Å
α=90.00° β=129.305(2)° γ=90.00°
C18H22N2O2
C18H22N2O2
Organic letters (2007) 9, 24 5119-5122
a=8.5329(17)Å b=10.238(2)Å c=18.578(4)Å
α=90.00° β=102.188(3)° γ=90.00°
C16H18N2O2
C16H18N2O2
Organic letters (2007) 9, 24 5119-5122
a=8.479(19)Å b=22.03(5)Å c=8.403(19)Å
α=90.00° β=116.06(4)° γ=90.00°
(1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione).(1,4- butanedicarboxylic acid)
C8H10N4O2,C6H10O4
Chemical communications (Cambridge, England) (2007) 5 525-527
a=9.5480(16)Å b=9.5862(16)Å c=9.6682(16)Å
α=82.705(3)° β=87.649(3)° γ=67.236(2)°
C18H18NO2
C18H18NO2
CrystEngComm (2010) 12, 5 1485
a=5.721(3)Å b=11.617(5)Å c=24.595(11)Å
α=93.910(8)° β=90.624(8)° γ=103.852(8)°
C18H18NO2
C18H18NO2
CrystEngComm (2010) 12, 5 1485
a=5.702(3)Å b=11.600(7)Å c=24.523(14)Å
α=93.589(13)° β=90.734(12)° γ=103.756(11)°
C18H22NO2
C18H22NO2
CrystEngComm (2010) 12, 5 1485
a=5.725(2)Å b=48.556(19)Å c=11.522(4)Å
α=90.00° β=103.316(8)° γ=90.00°
2(C13H18O2),C10H8N2
2(C13H18O2),C10H8N2
CrystEngComm (2010) 12, 5 1485
a=5.7654(4)Å b=48.700(3)Å c=11.5146(7)Å
α=90.00° β=103.6840(10)° γ=90.00°
2(C13H18O2),C10H8N2
2(C13H18O2),C10H8N2
CrystEngComm (2010) 12, 5 1485
a=5.7162(12)Å b=11.563(3)Å c=24.621(5)Å
α=94.133(5)° β=90.210(3)° γ=104.275(3)°
C8H9O2N1,1.5(C12H10N2),4(O1H2)
C8H9O2N1,1.5(C12H10N2),4(O1H2)
CrystEngComm (2013) 15, 24 4816
a=8.4243(14)Å b=12.227(2)Å c=13.193(2)Å
α=96.960(2)° β=93.427(2)° γ=101.280(2)°
C8H9O2N1,1.5(C12H10N2),2(O1H2)
C8H9O2N1,1.5(C12H10N2),2(O1H2)
CrystEngComm (2013) 15, 24 4816
a=9.2028(9)Å b=11.5290(12)Å c=11.7206(12)Å
α=93.3410(10)° β=99.5260(10)° γ=102.8040(10)°
C8H9O2N1,C12H10N2,2(O1H2)
C8H9O2N1,C12H10N2,2(O1H2)
CrystEngComm (2013) 15, 24 4816
a=6.5584(5)Å b=40.426(3)Å c=7.1631(5)Å
α=90.00° β=97.5890(10)° γ=90.00°
2(C8H9N1O2),C12H10N2,C2H5O1
2(C8H9N1O2),C12H10N2,C2H5O1
CrystEngComm (2013) 15, 24 4816
a=8.835(3)Å b=10.724(3)Å c=15.174(4)Å
α=91.638(4)° β=100.515(4)° γ=106.191(4)°
C17H20N2O2
C17H20N2O2
Organic letters (2007) 9, 24 5119-5122
a=18.610(4)Å b=7.6918(18)Å c=20.026(5)Å
α=90.00° β=90.00° γ=90.00°
Fenofibrate
C20H21ClO4
Acta Crystallographica Section E (2003) 59, 5 o699-o700
a=8.1605(16)Å b=8.2664(16)Å c=14.511(3)Å
α=93.951(3)° β=105.664(3)° γ=96.002(3)°
C16H36Cl6O10Pr2
C16H36Cl6O10Pr2
Acta Crystallographica Section C (1992) 48, 6 1099-1101
a=8.564(5)Å b=9.439(9)Å c=9.566(5)Å
α=86.01(9)° β=72.30(6)° γ=78.09(9)°
Ciprofloxacin hemi-methanolate
C17H18FN3O3,0.5(C1H4O1)
Acta Crystallographica Section E (2006) 62, 12 o5803-o5805
a=26.036(11)Å b=12.697(5)Å c=10.235(4)Å
α=90.00° β=100.941(7)° γ=90.00°
C32H47O2P
C32H47O2P
ACS Catalysis (2019) 11691
a=12.342(3)Å b=19.352(5)Å c=13.400(3)Å
α=90.00° β=99.229(3)° γ=90.00°
C31H47O0.33P
C31H47O0.33P
ACS Catalysis (2019) 11691
a=19.350(3)Å b=19.350(3)Å c=38.469(14)Å
α=90.00° β=90.00° γ=120.00°
L_5f
C36H53O3P
ACS Catalysis (2019) 11691
a=8.5680(10)Å b=9.1013(11)Å c=23.827(3)Å
α=80.6490(10)° β=86.3570(10)° γ=63.9230(10)°
C34H51O4P
C34H51O4P
ACS Catalysis (2019) 11691
a=9.9251(8)Å b=11.2824(9)Å c=28.061(2)Å
α=90° β=96.4210(10)° γ=90°
L_5k
C40H59O4P,0.5(CH2Cl2)
ACS Catalysis (2019) 11691
a=11.6617(18)Å b=12.3698(19)Å c=14.951(2)Å
α=100.424(2)° β=92.731(2)° γ=115.736(2)°
Ox_5c
C41H55BrNO4PPd,1.5(CH2Cl2)
ACS Catalysis (2019) 11691
a=11.542(2)Å b=11.548(2)Å c=17.998(3)Å
α=81.507(2)° β=77.635(2)° γ=72.621(2)°
AdBrettPhos
C43H61O2P,0.06(H2O)
ACS Catalysis (2019) 11691
a=12.838(4)Å b=16.357(5)Å c=19.029(5)Å
α=97.751(4)° β=102.559(4)° γ=102.096(4)°
Ox_5f
C43H57BrNO3PPd,1.5(C7H8)
ACS Catalysis (2019) 11691
a=17.7459(8)Å b=19.0935(8)Å c=53.801(3)Å
α=90° β=90° γ=90°
Ox_5k
C47H63BrNO4PPd
ACS Catalysis (2019) 11691
a=13.126(9)Å b=11.472(8)Å c=28.93(2)Å
α=90° β=91.981(10)° γ=90°
Ox_5j
C46H61BrNO3PPd,0.5(C5H12),CH2Cl2
ACS Catalysis (2019) 11691
a=27.660(13)Å b=21.676(10)Å c=19.545(9)Å
α=90° β=123.911(5)° γ=90°
Cpx_5c
C46H69F3NO7PPdS,C7H8
ACS Catalysis (2019) 11691
a=12.4741(4)Å b=16.7555(6)Å c=14.1454(5)Å
α=90° β=115.680(2)° γ=90°
Cpx_5f
C48H71F3NO6PPdS
ACS Catalysis (2019) 11691
a=28.3488(4)Å b=18.5998(3)Å c=19.6316(3)Å
α=90° β=112.7010(10)° γ=90°
Cpx_5j
C51H75F3NO6PPdS
ACS Catalysis (2019) 11691
a=15.0843(4)Å b=17.9837(5)Å c=19.7605(5)Å
α=90° β=108.1210(10)° γ=90°
Theopylline 3,5-dihydroxybenzoic acid complex
C7H8N4O2,C7H6O4
Crystal Growth & Design (2014) 14, 10 5318
a=7.2253(17)Å b=7.9998(19)Å c=12.650(3)Å
α=81.240(4)° β=85.071(4)° γ=82.509(4)°
Theopylline 3-hydroxybenzoic acid complex
C7H8N4O2,C7H6O3
Crystal Growth & Design (2014) 14, 10 5318
a=7.683(2)Å b=8.191(2)Å c=23.307(6)Å
α=98.202(5)° β=92.589(5)° γ=103.123(4)°
Theopylline 2,3-dihydroxybenzoic acid complex
C7H8N4O2,C7H6O4
Crystal Growth & Design (2014) 14, 10 5318
a=15.327(7)Å b=6.792(3)Å c=14.041(6)Å
α=90.00° β=106.297(4)° γ=90.00°
Theopylline 2,4-dihydroxybenzoic acid complex
C7H8N4O2,C7H6O4
Crystal Growth & Design (2014) 14, 10 5318
a=12.565(4)Å b=7.894(3)Å c=14.528(5)Å
α=90.00° β=98.840(6)° γ=90.00°
Theopylline 2,6-dihydroxybenzoic acid salt monohydrate
C7H9N4O21,C7H5O41,O1H2
Crystal Growth & Design (2014) 14, 10 5318
a=14.6593(19)Å b=6.5583(8)Å c=15.727(2)Å
α=90.00° β=94.0430(10)° γ=90.00°
Theopylline 3,4-dihydroxybenzoic acid complex
C7H8N4O2,C7H6O4
Crystal Growth & Design (2014) 14, 10 5318
a=8.0694(12)Å b=8.5782(13)Å c=11.5578(17)Å
α=103.147(2)° β=104.970(2)° γ=105.358(2)°
2(C13H17BrNO2),C4H4O6
2(C13H17BrNO2),C4H4O6
Journal of Organic Chemistry (2009) 74, 4886-4889
a=15.900(4)Å b=6.2937(17)Å c=16.234(4)Å
α=90.00° β=107.461(4)° γ=90.00°
C34H42N2O7
C34H42N2O7
Journal of Organic Chemistry (2005) 70, 3332-3335
a=10.4915(3)Å b=16.6596(4)Å c=17.7783(4)Å
α=90.00° β=90.00° γ=90.00°
C38H48N4O7
C38H48N4O7
Journal of Organic Chemistry (2005) 70, 3332-3335
a=11.8288(3)Å b=17.1521(4)Å c=17.8083(5)Å
α=90.00° β=90.00° γ=90.00°
C14H14N4O5S
C14H14N4O5S
Journal of the American Chemical Society (2006) 128, 16206-16212
a=8.455(9)Å b=17.191(18)Å c=10.498(11)Å
α=90.00° β=101.633(18)° γ=90.00°
C14H14N4O5S
C14H14N4O5S
Journal of the American Chemical Society (2006) 128, 16206-16212
a=15.722(1)Å b=13.1530(8)Å c=8.0242(5)Å
α=90.0000° β=95.403(4)° γ=90.0000°
C14H14N4O5S
C14H14N4O5S
Journal of the American Chemical Society (2006) 128, 16206-16212
a=15.677(5)Å b=13.127(4)Å c=8.019(2)Å
α=90.00° β=95.390(6)° γ=90.00°
C15H16N4O5S1
C15H16N4O5S1
Journal of the American Chemical Society (2006) 128, 16206-16212
a=13.760(6)Å b=14.269(6)Å c=16.488(7)Å
α=90.00° β=90.00° γ=90.00°
Sulfadiazine 4-picoline cocrystal
C10H10N4O2S,C6H7N
Crystal Growth & Design (2013) 13, 1 393
a=7.834(5)Å b=9.005(5)Å c=12.310(7)Å
α=79.922(7)° β=83.513(6)° γ=70.167(6)°
Sulfadiazine 4,4-bipyridine
(C10H10N4O2S)2,(C10H8N2)3
Crystal Growth & Design (2013) 13, 1 393
a=10.7093(13)Å b=14.1126(17)Å c=15.9739(19)Å
α=90.1960(10)° β=105.5040(10)° γ=91.4720(10)°
Sulfadiazine 1,2-bis(4-pyridyl)acetylene
C10H10S1O2N4,(C12H8N2)0.5
Crystal Growth & Design (2013) 13, 1 393
a=5.734(3)Å b=8.057(4)Å c=18.163(10)Å
α=78.438(7)° β=81.646(8)° γ=77.011(7)°
4-(pyridinium-4-yl)piperazine sulfadiazinide
C10H9N4O2S1,C9H14N31
Crystal Growth & Design (2013) 13, 1 393
a=9.3362(13)Å b=15.684(2)Å c=13.6864(18)Å
α=90.00° β=105.497(4)° γ=90.00°
Sulfadiazine (E)-1,2-bis(4-pyridyl)ethylene
C10H10S1O2N4,(C12H10N2)0.5
Crystal Growth & Design (2013) 13, 1 393
a=5.7617(12)Å b=7.9548(17)Å c=18.104(4)Å
α=98.292(4)° β=98.831(3)° γ=102.779(3)°
C10H9N4O2S,C7H11N2
C10H9N4O2S,C7H11N2
Crystal Growth & Design (2013) 13, 1 393
a=9.1978(10)Å b=15.1948(16)Å c=13.3595(14)Å
α=90° β=109.537(5)° γ=90°
C8H10N4O2,C7H6O3
C8H10N4O2,C7H6O3
Crystal Growth & Design (2009) 9, 4 1932
a=14.771(3)Å b=7.0212(14)Å c=16.209(3)Å
α=90.00° β=117.194(3)° γ=90.00°
C8H10N4O2,C7H6O3
C8H10N4O2,C7H6O3
Crystal Growth & Design (2009) 9, 4 1932
a=7.687(3)Å b=6.948(3)Å c=28.098(11)Å
α=90.00° β=95.029(7)° γ=90.00°
C8H10N4O2,2(C7H6O3)
C8H10N4O2,2(C7H6O3)
Crystal Growth & Design (2009) 9, 4 1932
a=7.421(5)Å b=22.494(15)Å c=12.939(9)Å
α=90.00° β=92.242(12)° γ=90.00°
2(C8H10N4O2),C7H6O3
2(C8H10N4O2),C7H6O3
Crystal Growth & Design (2009) 9, 4 1932
a=9.938(4)Å b=16.537(6)Å c=14.758(6)Å
α=90.00° β=101.096(6)° γ=90.00°
C7H6O4,C8H10O2N4,O1H2
C7H6O4,C8H10O2N4,O1H2
Crystal Growth & Design (2009) 9, 4 1932
a=6.657(4)Å b=8.796(5)Å c=15.670(9)Å
α=77.832(9)° β=83.426(9)° γ=71.568(9)°
C8H10N4O2,C7H6O4,H2O
C8H10N4O2,C7H6O4,H2O
Crystal Growth & Design (2009) 9, 4 1932
a=7.201(3)Å b=8.620(4)Å c=13.822(6)Å
α=90.258(7)° β=101.078(7)° γ=106.517(7)°
C8H10N4O2,C7H6O4,H2O
C8H10N4O2,C7H6O4,H2O
Crystal Growth & Design (2009) 9, 4 1932
a=7.015(2)Å b=7.693(2)Å c=30.319(9)Å
α=90.00° β=90.594(5)° γ=90.00°
TBuBrettPhos
C31H49O2P
ACS Catalysis (2019) 11691
a=18.317(3)Å b=13.782(2)Å c=22.811(4)Å
α=90° β=90° γ=90°
C10H9N4O2S,C5H7N2
C10H9N4O2S,C5H7N2
Crystal Growth & Design (2013) 13, 1 393
a=11.9647(13)Å b=8.6341(10)Å c=15.8757(17)Å
α=90° β=95.112(5)° γ=90°